| Market Capitalization (Millions $) |
1,082 |
| Shares
Outstanding (Millions) |
104 |
| Employees |
131 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-205 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Olema Pharmaceuticals Inc. is a clinical stage biopharmaceutical company that focuses on the development of novel cancer therapies. The company is headquartered in San Francisco, California and was founded in 201 Its mission is to develop innovative therapies that can improve the lives of patients who are suffering from cancer, by identifying and targeting cancer-specific vulnerabilities.
Olema's flagship drug candidate is known as OP-1250. It is a first-in-class small molecule that targets the estrogen receptor (ER) alpha and covalently binds to a cysteine residue to create a unique pharmacological profile that leads to sustained anti-tumor activity across multiple tumor types. The company believes that OP-1250 could become a superior estrogen receptor antagonist compared to existing drugs on the market, especially in breast cancer treatment.
Olema's research is based on the unique biology of cancer and how tumor cells grow and respond to different stimuli. The team at Olema is focused on developing targeted therapies that will be effective against specific types of cancers. In addition to its work on OP-1250, Olema is also developing other small molecule drugs simultaneously.
The CEO of Olema is Sean P. Bohen, M.D., Ph.D., who has over 20 years of experience in the pharmaceutical industry, including leadership roles at companies like AstraZeneca, Merck, and Genentech. He has assembled a strong team of experts in oncology drug development, clinical research, and regulatory affairs to help achieve Olema's goals.
As of August 2021, Olema Pharmaceuticals Inc. had a market capitalization of about $8 billion. The company has raised over $507 million in equity financing as well as receiving grants and awards from public and private entities.
In summary, Olema Pharmaceuticals Inc. is a clinical-stage company focused on developing targeted therapies for cancer treatment, with its leading drug candidate, OP-1250. The company has a strong management team, a solid research pipeline, and has received significant financial support from investors and from public and private grants. Olema is committed to bringing innovative therapies to patients living with cancer, making a difference in the world by improving treatments for cancer.
Company Address: 780 Brannan Street San Francisco 94103 CA
Company Phone Number: 651‑3316 Stock Exchange / Ticker: NASDAQ OLMA
|
